The plasminogen activators urokinase and tissue plasminogen activator are enzymes that degrade proteins in tissue basement membranes and the extracellular matrix (a biomolecular complex surrounding individual cells in tissues that serves as a barrier between the cells and the vascular and lymph systems). The action of these enzymes allows tumor cells to escape their local environment and metastasize. Plasminogen activator activity can be influenced by the urokinase receptor, which is expressed on the surface of cells, and by the plasminogen activator inhibitors 1 and 2. Because bladder tumors differ in their propensity to invade local areas and distant sites, we studied the expression of both plasminogen activators, the two plasminogen activator inhibitors, and the urokinase receptor in four human bladder cancer cell lines (RT4, 253J, EJ, and T24) to see if there was an association between the expression of these proteins and tumor cell invasiveness in vitro. Methods: The expression of urokinase, tissue plasminogen activator, and the two inhibitors was measured by enzyme-linked immunosorbent assays of serum-free, cellconditioned media (i.e., culture fluids). Cell surface expression of the urokinase receptor was assayed by flow cytometry, using an anti-receptor monoclonal antibody (Mab3936). The invasive capacity of untreated cells and of cells exposed to exogenous, highmolecular-weight urokinase was ana-
Components of the plasminogen activator system provide important mechanisms for tumor implantation, local tumor invasion, and metastasis in many forms of cancer (1) , but these components have not yet been well studied in bladder cancer. In general, plasminogen activators are thought to degrade extracellular matrix proteins and cellular basement membranes and to allow local tumor invasion and access to the vascular and lymph systems for metastasis. Urokinase (u-PA) is the most common form of plasminogen activator associated with cancers, although a few cancers secrete predominantly tissue plasminogen activator (t-PA) (2) . The inhibitors of plasminogen activation, PAI-1 and PAI-2, have also been described in association with different types of cancer, and their roles are still being defined (1, (3) (4) (5) (6) (7) (8) (9) (10) (11) . PAI-1 may help focus areas of proteolysis, has a protective effect in preventing degradation of tumor cells, and facilitates circulating tumor cell reimplantation (7) . The u-PA receptor (u-PAR) is hypothesized to focus and prolong effective plasminogen activation, enhancing basement membrane destruction and tumor invasion while preventing inactivation by inhibitors (1, 12, 13) . u-PA must bind to u-PAR on the surface of cells for invasion (degradation of the extracellular matrix and basement membrane) to occur in other tumor systems (14) . Many tumors have been shown to express the u-PAR (15) (16) (17) (18) (19) , and its expression has been associated with cell migration and tumor invasion (20) (21) (22) (23) .
Only a few early reports have related components of the plasminogen activator system to bladder cancer. Preliminary reports (24) (25) (26) (27) (28) (29) have shown increased levels of plasminogen activators in association with urothelial cancers. High u-PA antigen levels in bladder tumor extracts were found to be directly associated with advancing stage and grade of bladder tumor (26) (27) (28) 30) , and an increased u-PA antigen level has been suggested as a poor prognosticator in bladder cancer patients (30) . PAI-1 has also been shown to be associated with bladder cancers of a higher grade and stage (30) . A direct association has been found between u-PAR expression and increasing grade and stage of bladder tumor (30) .
The purpose of this study is to quantitate the two plasminogen activators (u-PA and t-PA) and their inhibitors (PAI-1 and PAI-2) and to determine the expression of u-PAR in four human transitional cell carcinoma lines (RT4, 253J, EJ, and T24) and to see if there was an association between these factors and invasion of artificial basement membrane (i.e., Matrigel).
Materials and Methods

Tumor Cell Lines
The RT4 cell line was developed from a primary transitional cell carcinoma of the bladder with both papillary and solid components demonstrating superficial muscle invasion (31) . The T24 cell line was developed from a primary grade 3 transitional cell carcinoma of the bladder (depth of invasion unknown) (32) . The 253J cell line was developed from a retroperitoneal metastasis from a patient with multiple transitional cell tumors of the urinary tract (33) . The EJ cell line was developed from an invasive, poorly differentiated transitional cell carcinoma of the bladder (34, 35) . The RT4, 253J, and T24 cell lines were obtained from Dr. Timothy L. Ratliff at Washington University, St. Louis, MO. The EJ cell line was obtained from Dr. Kevin Scanlon at City of Hope Hospital, Duarte, CA. The HT1080 cell line, derived from a human fibrosarcoma (ATCC CCL121; American Type Culture Collection, Rockville, MD), is known to express the u-PAR (17, 36) and was used as a positive control in our studies. The 3T3 cell line (ATCC CRL 6442; American Type Culture Collection) is known to lack the u-PAR (15) and was used as a negative control in our studies.
The RT4 and T24 cell lines were grown in minimal essential medium (MEM) supplemented with 10% fetal calf serum, 1% L-glutamine, and 0.05% penicillin-streptomycin. The 253J cell line was grown in Dulbecco's modified Eagle medium (DMEM) supplemented with insulin (5 g/mL), transferrin (5 g/mL), thyroxine (0.0136 g/mL), biotin (0.244 g/mL), adenine (25 g/mL), 10% fetal calf serum, and 0.05% penicillin-streptomycin. The EJ cell line was grown in RPMI-1640 medium supplemented with 10% fetal calf serum and 0.05% penicillin-streptomycin. The HT1080 cell line was grown in DMEM supplemented with 10% fetal calf serum and 0.05% penicillin-streptomycin. The 3T3 cell line was grown in DMEM supplemented with 2 mM glutamine, 10% fetal calf serum, and 0.05% penicillin-streptomycin. Medium was replaced every 3 days, and the cells were subcultured when they reached 80% confluence.
Determination of Components of the Plasminogen Activator System
Cells (1 × 10 6 ) from each line were transferred to 35-mm Petri dishes (Costar, Cambridge, MA) and subcultured in 5 mL serum-free medium for 72 hours. Because fetal calf serum may contain exogenous components of the plasminogen activator system, use of serum-free media was necessary to measure only the plasminogen activator components associated with the tumor cells themselves. Cell viability was monitored at 24-hour intervals by use of trypan blue dye exclusion to detect nonviable cells. Greater than 95% of cells remained viable in serumfree media during the 72-hour period. The serumfree, cell-conditioned medium samples were prepared by removing the supernatant (5 mL) from the 10 6 cells and filtering it through a 0.2-m filter. The serum-free, cell-conditioned medium samples were either used immediately or stored at −70°C. The protein antigen levels measured in the serum-free, cell-conditioned media represent the secretion of protein by 10 6 cells into 5 mL of serum-free medium over a 72-hour period. ELISAs for u-PA and t-PA Antigen Levels u-PA and t-PA antigen levels were measured by use of commercially available ELISA kits (products ն894 and ն860, respectively; American Diagnostica, Greenwich, CT). Both kits are based on a double-antibody sandwich technique in which two different monoclonal antibodies are used for capture and detection of the antigen. The u-PA ELISA detects free forms of u-PA, i.e., single-chain u-PA and high-molecular-weight forms of u-PA, as well as bound forms of u-PA, i.e., receptor-bound u-PA and u-PA complexed with PAI-1 and PAI-2. Samples were run in octets for each experiment. The means ± standard deviations for two separate trials are shown in Table 1 .
ELISAs for PAI-1 and PAI-2 Antigen Levels
PAI-1 and PAI-2 antigen levels were also measured by use of commercially available ELISA kits (products ն821 and ն823; American Diagnostica). These kits also use a double-antibody sandwich technique employing two different monoclonal antibodies for capture and detection of the antigen. The PAI-1 assay detects latent (inactive) and active forms of PAI-1 and PAI-1 complexes, but it is insensitive to PAI-2. The PAI-2 assay detects both the low-molecular-mass (48 kd) form and the high- 5 cells cultured in serum-free medium for 72 hours. †Values ‫ס‬ means ± standard deviations. Pairwise comparisons of the protein antigen levels secreted into the serum-free, cell-conditioned media by the different bladder tumor cell lines were evaluated by the Mann-Whitney U test. The urokinase (u-PA) antigen levels associated with the EJ cells were significantly higher than those associated with all other cell lines tested (P<.0001). The tissue plasminogen activator (t-PA) antigen levels associated with the T24 cells were significantly higher than those associated with the other cell lines (P<.0001). The PAI-1 antigen levels associated with the T24 cells were significantly higher than those associated with the other cell lines tested (P<.001). Protein antigen levels associated with the cell lysates from the different bladder tumor cell lines were also compared by the Mann-Whitney U test. The u-PA antigen levels associated with the cell lysates of the EJ and 253J cells were significantly higher than those associated with the T24 cells (P<.02), but not significantly different from those associated with the RT4 cell lysate. molecular-mass (60 kd) glycosylated form. Both free PAI-2 and PAI-2/u-PA complexes are recognized by this assay. The PAI-2 assay is insensitive to PAI-1. Samples were run in octets for each experiment. The means ± standard deviations for two separate trials for the PAI-1 and PAI-2 assays are shown in Table 1 .
Flow Cytometry for u-PARs
u-PARs were detected by use of the commercially available monoclonal antibody Mab3936 (American Diagnostica) directed against the u-PAR. Mab3936 has been shown to bind both bound and unbound u-PARs on the surface of tumor cells (37) . Fluorescence associated with single cells was quantified by flow cytometry (fluorescence-activated cell sorter) with the FACScan flow cytometer (Becton Dickinson Labware, San Jose, CA) (low-power argon laser excitation at 488 nm).
Living cells (1 × 10 6 ) were reacted with Mab3936 (2 g/mL) in RPMI-1640 medium containing 0.1% bovine serum albumin (BSA) at 22°C for 30 minutes as described by Chucholowski et al. (37) . Cells were then washed twice with RPMI-1640 medium containing 0.1% BSA and resuspended in the same medium containing fluorescein isothiocyanate (FITC)-anti-mouse immunoglobulin (Ig) G (4 g/ mL) at 22°C for 30 minutes. Cells were washed extensively with RPMI-1640 medium containing 0.1% BSA and then resuspended in 2.5 mL of the same medium. 7-Aminoactinomycin D (7AAD) was used to exclude nonviable cells. Cell-associated fluorescence was determined by flow cytometry (FACScan). Autofluorescence of the cells and nonspecific binding of the FITC-antibody in the absence of Mab3936 were subtracted from the total fluorescence for each determination. HT1080 cells, which express u-PARs (17, 36) , were used as a positive control; 3T3 cells, which do not express the receptor (15) , were used as a negative control. Flow cytometry results for the HT1080, 3T3, RT4, T24, EJ, and 253J cell lines are shown in graphic form (logarithmic scale) in Fig. 1 . Each experiment obtained 20 000 events (i.e., counting of 20 000 fluorescent cells) per sample. Three independent experiments were run, and similar results were obtained.
Immunohistochemical Staining for u-PARs
Cell pellets were prepared from the cell lines grown in tissue culture. Cells were detached from the flasks by use of 10 mM EDTA, washed twice in PBS, and resuspended in serum-free MEM. Cell pellets were obtained by centrifugation at 4°C at 1500 rpm for 8 minutes; they were then fixed in 10% formalin for 24 hours and embedded in paraffin. Pellets from the HT1080 (positive control) and 3T3 (negative control) cell lines were prepared similarly.
Immunohistochemical staining of such cell pellets for u-PAR expression was described previously (16) .
Immunohistochemical studies were performed on 5-m sections from formalin-fixed, paraffinembedded cell pellets, mounted on acid-cleaned glass slides, and heated for 1 hour at 55°C. Slides were dewaxed and dehydrated and then immersed for 30 minutes in absolute methanol containing 0.6% (vol/vol) hydrogen peroxide to quench endogenous peroxidase activity. After rehydration through graded solutions of ethanol and distilled water, sections were immersed in 10 mM citrate buffer (10 mM citrate monohydrate in distilled water [pH 6]) in plastic Coplin jars and subjected to microwave irradiation (600 W, 2450 MHz) for 4 minutes. After cooling to room temperature, slides were removed and placed in PBS (pH 7.4) for 10 minutes. Sections were overlaid with Mab3936 at 10 g/mL (American Diagnostica) for 18 hours in moisture chambers at 4°C. The avidin-biotin complex (ABC) peroxidase method was performed (Vectastain ABC Elite Mouse Universal Kit; Vector Laboratories, Inc., Burlingame, CA) (38) . Chromogenic development resulted from immersion of slides in 3,3Ј-diaminobenzidine tetrahydrochloride (Sigma Chemical Co., St. Louis, MO; 0.5 mg/mL, containing 0.003% [vol/ vol] hydrogen peroxide) for 10 minutes or less. The reaction was enhanced by brief exposure to 0.125% (vol/vol) osmium tetroxide. Tissue sections on slides were counterstained in Harris' hematoxylin and mounted under coverslips with a synthetic mounting medium. , 2500 iu, or 5000 iu) (American Diagnostica) for 1 hour before being placed in the invasion chambers. Mouse monoclonal antibody anti-protein kinase C (Sigma Chemical Co.) was used as the control antibody. Cells were incubated in the sealed invasion chambers for 36, 48, or 72 hours at 37°C in a 5% CO 2 atmosphere. Noninvasive cells were removed from the upper surface of the membrane with a cotton swab before staining with Diff-Quik stain and microscopically counting invasive cells on the underside of the membrane. Cells were counted at 250× magnification under oil immersion with a Leitz phase-contrast microscope, and 100 fields were counted.
Matrigel Invasion Assays
For the inhibition studies, the Matrigel invasion chambers and cells were prepared as described above with the following modifications: Cells (5 × 10 4 ) were pretreated with varying concentrations of Mab3936 (0 g/mL, 2.5 g/mL, 5 g/mL, 10 g/
the same concentrations) (Sigma Chemical Co.) for 15 minutes before being placed in the upper chambers. Mab3936 or control antibody was added to the upper chambers at 3-hour intervals for 24 hours. Additional antibody was added during the invasion assay to replace that potentially internalized by the cells and to block the expression of new u-PARs on the cell surface during the incubation period. After the last addition of antibody, the chambers were incubated another 12 hours so that the total incubation time was 36 hours. Membranes were removed and stained, and invading cells were counted as described above.
For these studies, HT1080 cells served as the positive control, and 3T3 cells were the negative control.
Statistical Analysis
Nonparametric tests were used to evaluate the data in the experiments described above. The Mann-Whitney U test was used for pairwise comparisons, whereas the Kruskal-Wallis test was used to compare data with more than two groups. The P values were obtained from two-sided tests.
Results u-PA Antigen Levels
High u-PA antigen levels were consistently detected in the serum-free, cellconditioned medium from the EJ cell line, whereas moderate and low levels were detected, respectively, from the serum-free, cell-conditioned medium from the 253J and RT4 cell lines (Table 1) . Cell lysates, which represent intracellular stores of u-PA, also showed less marked differential expression of the u-PA antigen than was noted in the serum-free, cell-conditioned medium.
t-PA Antigen Levels
The highest t-PA antigen levels were detected in the serum-free, cell-conditioned medium from the T24 cell line; moderate and low levels, respectively, were detected in the serum-free, cellconditioned media of the 253J and EJ cell lines (Table 1) . t-PA antigen levels were not detected in the medium from the RT4 cell line. Low t-PA levels were noted in association with the cell lysates ( Table 1) .
PAI-1 and PAI-2 Antigen Levels
The highest level of PAI-1 antigen was found in the serum-free, cellconditioned medium of T24 cells. PAI-1 antigen was also detectable in the serum-free, cell-conditioned media of the EJ and RT4 cell lines, but PAI-1 was not detected in the serum-free, cell-conditioned medium of the 253J cell line ( Table 1) . The T24 and RT4 cell lysates showed detectable PAI-1 antigen levels, whereas the EJ and 253J cell lysates did not.
PAI-2 antigen levels were detected in the serum-free, cell-conditioned medium of 253J cells and cell lysates of T24 cells.
Flow Cytometric Detection of the u-PAR
The T24, EJ, and 253J cells expressed the u-PAR, whereas the RT4 cells did not. The display of u-PAR by the HT1080, 3T3, RT4, T24, EJ, and 253J cell lines is shown in the A panels of Fig. 1 (logarithmic scale) .
Immunohistochemical Staining for u-PAR
When anti-u-PAR antibodies were used to detect the u-PAR on formalinfixed, paraffin-embedded tissue sections or cell pellets, staining was observed to be primarily cytoplasmic and/or to be associated with the plasma membrane (16, 19, 37) . T24 (Fig. 2, A) , 253J (Fig. 2,  D) , and EJ (Fig. 2, C) cells showed cytoplasmic staining by Mab3936, whereas RT4 cells (Fig. 2, B) did not. Cells vary in the amount of associated cytoplasm, and some ''naked nuclei'' (those without associated cytoplasm) may be generated during processing; thus, brown staining is not associated with all of the T24 cells. The absence of brown staining in all of the cells of the RT4 cell pellet in Fig. 2 , B, suggests that these cells are not immunoreactive for the u-PAR.
Matrigel Invasion Chamber Assays
The 253J and EJ cell lines demonstrated the capacity to invade Matrigel when compared with 3T3 cells (lowinvasive-potential, negative control). They did not have the same invasive potential as the highly invasive HT1080 cells that were used as the positive control (Fig. 1, B panels) . As shown above, 253J cells and EJ cells expressed moderate to high levels of u-PA, moderate to low levels of t-PA, and the u-PAR. Expression of high levels of t-PA in the presence of the u-PAR and minimal amounts of u-PA (T24 cells) did not yield appreciable invasion, suggesting that t-PA does not substantially influence bladder tumor cell invasion of Matrigel. A failure to express the u-PAR, even in the presence of u-PA (RT4 cells), was, however, associated with a failure to invade Matrigel. The secretion of PAI-1 or PAI-2 did not appear to influence invasion under the conditions tested.
Pretreatment of the cell lines with exogenous, high-molecular-weight urokinase to occupy the u-PAR enhanced the ability of cells expressing this receptor (253J, EJ, and T24, plus HT1080) to invade Matrigel, but it did not affect the invasive potential of cells lacking the u-PAR (RT4, plus 3T3). Pretreatment of T24 cells, which produce only minimal amounts of u-PA, with high-molecularweight u-PA converted these cells from being noninvasive to being invasive in vitro (Fig. 1, B panel) .
Pretreatment of cells with the antiu-PAR antibody Mab3936, which is known to bind to both occupied and unoccupied receptors, blocked the invasion of Matrigel by the EJ cell line-the most naturally invasive of the bladder cancer cell lines tested-that expressed the u-PAR and produced u-PA (Fig. 3, A) . The anti-u-PAR antibody Mab3936 also inhibited Matrigel invasion by u-PApretreated T24 cells (Fig. 3, B) .
Discussion
Both in vitro (24, 25, 39) and in vivo (26) (27) (28) 30 ) evidence of plasminogen activator activity has been reported in bladder cancer. In this study, u-PA production and t-PA production were demonstrated by different bladder tumor cell lines.
u-PA is the predominant plasminogen activator found in association with urothelial cancers. We confirmed this finding in three (RT4, EJ, and 253J) of the four cell lines tested. u-PA production alone did not predict tumor invasiveness, although the tumor cell lines producing the highest levels of u-PA were invasive in vitro.
Dubeau et al. (24) suggested that t-PA is not produced by bladder cancer cells. We disagree. T24 cells produce predominantly t-PA, and moderate and low levels are produced by 253J and EJ cells, respectively. Prior to H-ras transfection, murine BL tumor cells produced predominantly t-PA (25) . t-PA is the predominant plasminogen activator produced by other well-established tumor cell lines (2) . We hypothesize that t-PA production is possible by some bladder tumors, although its role in bladder tumor invasion is not yet defined. It is possible that t-PA could play a role in bladder tumor implantation at sites of fibrin clot deposition after tumor resection, since t-PA is known to have a high affinity for fibrin clots.
An inverse relationship between u-PA production and t-PA production was observed in the bladder tumor cell lines. A similar inverse relationship has been observed in breast (5) and colon (40) cancers, although the significance of this finding is unknown. t-PA and u-PA are known to be regulated at different gene locations, u-PA but not t-PA binds to a ) was used at concentrations of 0 g/mL, 2.5 g/mL, 5 g/mL, 10 g/mL, 15 g/mL, and 20 g/mL on the EJ cells (A) and u-PA-pretreated T24 cells (B). Mab3936 or control antibody was used to pretreat EJ cells or u-PA-pretreated T24 cells, and cells were pulsed with additional antibody at 3-hour intervals during the first 24 hours of the invasion assay. After the last addition of antibody, the chambers were incubated for another 12 hours so that the total incubation time was 36 hours. The Mann-Whitney U test demonstrates a significant inhibitory effect by the anti-u-PA receptor antibody compared with the control antibody at concentrations ജ15 g/mL (Pഛ.005 for each cell line). Two separate experiments showed similar results by the MannWhitney U test, indicating no significant difference between the results of experiments 1 and 2. To simplify the graph, the results are expressed as the means ± standard deviations from the two experiments on each cell line. specific receptor (u-PAR), and growth factors have been shown to have independent effects on the production of u-PA and t-PA. Differences in the culture media used for the different bladder tumor cell lines may have influenced the components of the plasminogen activator system produced in these studies.
Carmeliet et al. (41) have suggested a complementary role between u-PA and t-PA in other biologic processes. Both plasminogen activators can be inhibited by PAI-1 and PAI-2, and both compete for the same substrate-plasminogen. One form of plasminogen activator-or more likely an increase in the protein degradation products produced by plasmin activation-could exert an inhibitory effect on production of the other. Growth factors, cytokines, extracellular matrix proteins or their degradation products, or other undetermined factors present at the site of the primary or metastatic lesion may influence the type of plasminogen activator produced. Further work is needed to clarify the regulatory mechanisms for plasminogen activator production in bladder cancer.
PAI-1 inhibits both free and receptorbound u-PA and t-PA. Plasminogen activator inhibitors likely inhibit tumor implantation, invasion, and metastasis in all tumor systems. Exceptions to this rule are, however, described. PAI-1 production has been found to be associated with the presence of lymph node metastases, higher relapse rates, and decreased survival in breast and lung cancer patients (3, 5, 6) . PAI-1 may direct proteolytic activity on the cell surface by internalization of u-PA/PAI-1 complexes, allowing polarized, focal proteolysis on the cell surface (7). PAI-1 has not been found in surrounding normal tissue, and its presence in tumor tissue may protect tumor cells against degradation by activated plasmin. Lymph node metastases have been observed to have higher PAI-1 antigen content than the associated primary breast tumor (8) . Secretion of PAI-1 may facilitate reimplantation of circulating tumor cells at distant sites (5) . Production of PAI-1 does not prevent metastasis of all tumor types and may actually enhance the metastatic potential of some tumors. Thus, it is not incongruous that both invasive and noninvasive bladder tumor cell lines produce PAI-1.
The role of PAI-2 in malignant disease is ill-defined. PAI-2 has been described as a less efficient but more specific inhibitor of u-PA than PAI-1 (1). PAI-2 is not efficiently secreted into the extracellular matrix, and it is suggested to be an inhibitor of intracellular proteases (9) . PAI-2 is thought by some investigators (4, 10, 11) to inhibit cancer cell invasion and metastasis in vitro and in vivo. However, the presence of high levels of PAI-2 antigen in tumor tissue is a good prognostic factor for some tumor types but a poor prognostic factor for others (10, 42) . Our studies show that detectable levels of PAI-2 are found in association with the serum-free, cell-conditioned medium of 253J cells and T24 cell lysates. The latter finding is compatible with results from other studies showing that PAI-2 is usually located intracellularly (10) . The role of PAI-2 in bladder cancer needs further investigation.
A number of studies (1, 14, (43) (44) (45) confirm that u-PA must bind to the cell surface u-PAR for tumor cell invasion and metastasis to occur. The u-PAR binds pro-u-PA, which is then converted to its active form. It strongly enhances the production of surface-bound plasmin, which is protected from inactivation by alpha 2 -antiplasmin (44) . The u-PAR has been found at foci of tumor invasion (43, 45) and has been suggested to be a poor prognostic factor in several tumor types (43, 46) . Both melanoma and osteosarcoma cell lines expressing u-PA and the u-PAR have been shown to be invasive (20, 21) . u-PA and the u-PAR facilitate migration of nonmalignant cells as well (22, 23) .
In vitro studies (47) have shown that human colon carcinoma cell lines expressing the u-PAR but without u-PA production could not initially breakdown extracellular matrix. When these cells were transfected with u-PA complementary DNA and were able to produce u-PA, they developed the capacity to invade artificial basement membrane in vitro (47) . In our study, T24 cells expressed the u-PAR but secreted minimal amounts of u-PA. Our studies have shown that the T24 cell line alone is noninvasive in Matrigel invasion assays but it develops an invasive capacity when pretreated with high-molecular-weight u-PA. In colon cancer, the source of u-PA production may be stromal fibroblasts, not the carcinoma cells (45) ; these data suggest a similar possibility in bladder cancer. Thus, a bladder cancer cell (like the T24 cell) may be noninvasive until u-PA becomes available from another cell, whereupon it then exhibits an invasive phenotype. Despite secretion of detectable levels of u-PA, the RT4 cell line appears to be noninvasive in this study as well as in another study (48) because it lacks the efficient proteolysis that expression of the u-PAR may confer. The 253J and EJ cell lines, which both secrete u-PA and express the u-PAR, are invasive in vitro. These data suggest that an invasive bladder tumor requires both cells expressing the u-PAR and a source of u-PA if the plasminogen-plasmin system is responsible for tumor invasion. Pretreatment of the cell lines expressing the u-PAR with high-molecular-weight u-PA enhanced their invasive potential in Matrigel invasion chambers. Cell lines lacking the u-PAR did not develop the ability to invade Matrigel when they were pretreated with high-molecular-weight u-PA. Thus, neither production of u-PA alone nor the presence of the u-PAR without a source of u-PA was sufficient to allow tumor invasion in vitro.
Furthermore, blocking the binding of u-PA to the u-PAR has been shown to inhibit invasion and metastasis (49) (50) (51) (52) . Our study also suggests that blocking attachment of u-PA to the u-PAR prevents tumor invasion by bladder tumor cells in vitro.
In conclusion, this study adds new information by characterizing the differences in the components of the plasminogen activator system produced by four human bladder cancer cell lines. Differential expression of the u-PAR by these human bladder cancer cell lines was also a new finding. The most important new information from this study is that bladder tumor cells (not stromal or inflammatory cells in tumor extracts) produce u-PA, express the u-PAR, and require both u-PA and u-PAR for in vitro invasion by bladder cancer cells to occur. Furthermore, bladder tumor cell invasiveness can be enhanced by addition of exogenous u-PA to cells expressing the u-PAR and can be inhibited by antibodies directed against the u-PAR.
The implications of this study are important. Histologically similar bladder tumors often show marked differences in their propensity to invade locally or to metastasize. Differential expression of plasminogen activators, their inhibitors, and the u-PAR may affect the invasive and metastatic potential of human bladder cancers and offers one explanation for the aggressive or indolent tumor behavior observed in different bladder tumor patients. Elucidation of the mechanisms including the plasminogen activator system through which bladder tumor invasion and metastasis occur could lead to novel therapies for this disease. Further in vivo work is needed to confirm that the u-PAR and u-PA together are important for tumor invasion and/or metastasis. If so, then use of blocking antibodies against the u-PAR, use of inactive u-PA fragments to occupy the u-PAR, or enzymes (phosphatidylinositol-specific phospholipase C) to cleave the u-PAR from the cell surface could be considered in the prevention of bladder tumor invasion or metastasis.
